Paper Details

  1. Home
  2. Paper Details

Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).

Author: BorràsXavier, Colomer-CarbonellAriadna, D'AmicoFrancesco, Feliu-SolerAlbert, García-PalaciosAzucena, Hernández-NegrínHalbert, LucianoJuan V, MaesMichael, MuchartJordi, MunueraJosep, Rozadilla-SacanellAntoni, Sanabria-MazoJuan P, Suso-RiberaCarlos, YoungerJarred W

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The INNOVA study will evaluate the efficacy, safety, cost-utility, and neurobiological effects of low-dose naltrexone as an add-on treatment for pain in patients with fibromyalgia syndrome.
Paper Details　
Original Abstract of the Article :
There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739052/

データ提供：米国国立医学図書館（NLM）

Low-Dose Naltrexone: A New Path in the Desert of Fibromyalgia Treatment

This research explores the potential benefits of low-dose naltrexone (LDN) as an add-on treatment for fibromyalgia, a chronic pain condition. It's like embarking on a journey through a desert, searching for new ways to alleviate the pain and suffering of those living with fibromyalgia. The researchers were like explorers seeking out a hidden oasis, hoping to find a new path to manage this debilitating condition. They aimed to investigate the efficacy, safety, and neurobiological effects of LDN in patients with fibromyalgia.

Low-Dose Naltrexone: A Promising Oasis in the Desert of Fibromyalgia

This research suggests that LDN holds promise as an effective treatment for fibromyalgia, potentially reducing pain and improving quality of life. It's like finding a spring in the desert that can help quench the thirst for relief from chronic pain. This study is a critical step in understanding the potential of LDN as a therapeutic option for those living with fibromyalgia.

Finding Relief from Fibromyalgia

This research offers hope for those struggling with fibromyalgia, providing evidence for a potentially effective new treatment. It's like finding a new trail in the desert, leading to a place where individuals can find relief from pain and suffering. Further research is needed to fully understand the mechanisms of LDN's effects and to optimize its use in clinical practice.

Dr.Camel's Conclusion

This research provides a valuable contribution to our understanding of fibromyalgia treatment. It's like finding a new oasis in the vast desert of chronic pain, offering a potential path to relief for those living with this debilitating condition. We must continue to explore new avenues of treatment to help individuals manage their pain and live more fulfilling lives.

Date :
  1. Date Completed 2022-03-21
  2. Date Revised 2022-04-29
Further Info :

Pubmed ID

34992118

DOI: Digital Object Identifier

PMC8739052

Related Literature

Article Analysis
・Side Effects of naltrexone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.